Endologix Announces Leadership Transition

January 7, 2025—Endologix LLC announced that John Liddicoat, MD, has been appointed as President and CEO, effective immediately. Matt Thompson, MD, will step down as President and CEO. He will take on a new role with the company as Executive Vice President and Chief Medical Officer. 

According to Endologix, Dr. Liddicoat has more than 30 years of global health care experience. For more than 16 years, he served in executive roles at Medtronic leading strategic initiatives and overseeing global operations for critical divisions, including the cardiac rhythm and heart failure business, and has taken products from concept through product development to global commercial launch. 

“I’m excited to join Endologix as President and CEO and build upon the company's strong foundation,” commented Dr. Liddicoat in the company’s press release. “I look forward to collaborating with the team, to expand our impact, and improve outcomes for patients suffering from vascular disease around the world by delivering life-changing vascular solutions.”

Richard Mott, Chairman of the Board of Endologix, stated in the press release, “We are thrilled to welcome Dr. John Liddicoat as our new CEO. John’s extensive experience and proven leadership in the healthcare industry make him the ideal person to guide Endologix through its next chapter of growth and innovation.” 

Mott continued, “I also want to extend our sincere appreciation to Matt for his exceptional leadership and the significant advancements he has brought to Endologix during his tenure as CEO. We are pleased that Matt will remain an integral part of our team, enabling him to balance his professional commitments with a desire to spend more time in the United Kingdom.”